Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 6, 2009, Pages 1065-1071

  Lin, Chia Chi ^a,e   Calvo, Emiliano ^a,f   Papadopoulos, Kyriakos P ^a,g   Patnaik, Amita ^a,g   Sarantopoulos, John ^a   Mita, Alain C ^a   Preston, Glenn G ^b   Mita, Monica M ^a   Rodon, Jordi ^a,f   Mays, Theresa ^a,g   Yeh, I Tien ^c   O'Rourke, Pat ^a   Takimoto, Chris H ^a,g   Dancey, Janet E ^d   Chen, Helen ^d   Tolcher, Anthony W ^g  

^a CTRC Institute for Drug Development   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g South Texas Accelerated Research Therapeutics   (United States)

Author keywords

Epidermal growth factor receptor; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63949084255     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0811-x     Document Type: Article

References (36)

1. EK Rowinsky 2004 The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors Annu Rev Med 55 433 457
2. T Mukohara JA Engelman NH Hanna 2005 Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J Natl Cancer Inst 97 1185 1194
3. K Imai A Takaoka 2006 Comparing antibody and small-molecule therapies for cancer Nat Rev Cancer 6 714 727
4. S Huang EA Armstrong S Benavente 2004 Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 5355 5362
5. P Matar F Rojo R Cassia 2004 Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin Cancer Res 10 6487 6501
6. A Jimeno B Rubio-Viqueira ML Amador 2005 Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents Cancer Res 65 3003 3010
7. P Perrotte T Matsumoto K Inoue 1999 Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 5 257 265
8. CJ Bruns CC Solorzano MT Harbison 2000 Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res 60 2926 2935
9. F Ciardiello R Caputo R Bianco 2001 Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin Cancer Res 7 1459 1465
10. J Mendelsohn J Baselga 2003 Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2787 2799
11. YD Jung PF Mansfield M Akagi 2002 Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model Eur J Cancer 38 1133 1140
12. F Ciardiello R Bianco V Damiano 2000 Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 3739 3747
13. RM Shaheen SA Ahmad W Liu 2001 Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors Br J Cancer 85 584 589
14. D Schrag KY Chung C Flombaum 2005 Cetuximab therapy and symptomatic hypomagnesemia J Natl Cancer Inst 97 1221 1224
15. S Tejpar H Piessevaux K Claes 2007 Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study Lancet Oncol 8 387 394
16. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
17. FR Hirsch M Varella-Garcia PA Bunn Jr 2003 Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 3798 3807
18. JE Dancey HX Chen 2006 Strategies for optimizing combinations of molecularly targeted anticancer agents Nat Rev Drug Discov 5 649 659
19. J Baselga P Schoffski F Rojo 2006 A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC) J Clin Oncol (Meet Abstr) 24 3006
20. CL Naret S Ramalingam L Beattie 2006 Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: a phase I study for patients with recurrent non-small cell lung cancer (NSCLC) J Clin Oncol (Meet Abstr) 24 17045
21. Guarino MJ, Schneider CJ, Hosford MA et al (2007) Dual inhibition of the epidermal growth factor receptor (EGFR) pathway with the combination of cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Proc AACR-NCI-EORTC Mol Targets Cancer Ther 2007; abstract A147
22. EE Vokes EEW Cohen AM Mauer 2005 A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC) J Clin Oncol (Meet Abstr) 23 5504
23. RS Herbst DH Johnson E Mininberg 2005 Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2544 2555
24. JD Hainsworth JA Sosman DR Spigel 2005 Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib J Clin Oncol 23 7889 7896
25. L Fehrenbacher V O'Neill CP Belani 2006 A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer J Clin Oncol (Meet Abstr) 24 7062
26. G Friberg AM Oza RJ Morgan 2006 Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: preliminary results of a multi-center phase II trial J Clin Oncol (Meet Abstr) 24 5018
27. M Dickler H Rugo J Caravelli 2004 Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) J Clin Oncol (Meet Abstr) 22 2001
28. JD Hainsworth DR Spigel C Farley 2007 Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network J Clin Oncol 25 1747 1752
29. RM Bukowski FF Kabbinavar RA Figlin 2007 Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 4536 4541
30. LB Saltz HJ Lenz HL Kindler 2007 Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 4557 4561
31. GM Clark DM Zborowski JL Culbertson 2006 Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib J Thorac Oncol 1 837 846
32. JG Paez PA Janne JC Lee 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500
33. TJ Lynch DW Bell R Sordella 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139
34. W Pao V Miller M Zakowski 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306 13311
35. Z Wainberg JR Hecht 2006 A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer Clin Colorectal Cancer 5 363 367
36. JV Heymach BE Johnson D Prager 2007 Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer J Clin Oncol 25 4270 4277